Victory Capital Management
TEVA icon

Victory Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Victory Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.4M Sell
1,575,098
-263,339
-14% -$8.77M 0.03% 549
2026
Q1 		$55.4M Sell
1,838,437
-23,948
-1% -$770K 0.04% 490
2025
Q4 		$58.1M Sell
1,862,385
-498,377
-21% -$12.3M 0.03% 479
2025
Q3 		$47.7M Buy
2,360,762
+45,395
+2% +$797K 0.03% 578
2025
Q2 		$38.8M Sell
2,315,367
-1,094,775
-32% -$17.7M 0.03% 641
2025
Q1 		$52.4M Buy
3,410,142
+386,668
+13% +$6.91M 0.05% 441
2024
Q4 		$66.6M Buy
3,023,474
+1,094,759
+57% +$19.9M 0.07% 357
2024
Q3 		$34.8M Buy
1,928,715
+21,764
+1% +$381K 0.03% 615
2024
Q2 		$31M Buy
1,906,951
+107,909
+6% +$1.66M 0.03% 635
2024
Q1 		$25.4M Buy
1,799,042
+1,760,656
+4,587% +$22.2M 0.02% 727
2023
Q4 		$401K Buy
38,386
+6,886
+22% +$64.3K ﹤0.01% 2055
2023
Q3 		$321K Sell
31,500
-748
-2% -$6.96K ﹤0.01% 2105
2023
Q2 		$243K Sell
32,248
-8,198
-20% -$66.5K ﹤0.01% 2164
2023
Q1 		$358K Sell
40,446
-8,815
-18% -$87.2K ﹤0.01% 2096
2022
Q4 		$449K Sell
49,261
-126,499
-72% -$1.1M ﹤0.01% 2042
2022
Q3 		$1.42M Sell
175,760
-15,956
-8% -$141K ﹤0.01% 1577
2022
Q2 		$1.44M Buy
191,716
+6,662
+4% +$58K ﹤0.01% 1586
2022
Q1 		$1.61M Buy
185,054
+54,505
+42% +$455K ﹤0.01% 1590
2021
Q4 		$1.05M Buy
130,549
+10,851
+9% +$97.9K ﹤0.01% 1810
2021
Q3 		$1.17M Buy
119,698
+1,167
+1% +$10.9K ﹤0.01% 1791
2021
Q2 		$1.17M Sell
118,531
-20,611
-15% -$218K ﹤0.01% 1838
2021
Q1 		$1.61M Buy
139,142
+20,056
+17% +$230K ﹤0.01% 1709
2020
Q4 		$1.15M Buy
119,086
+35,886
+43% +$344K ﹤0.01% 1729
2020
Q3 		$750K Buy
83,200
+18,939
+29% +$200K ﹤0.01% 1825
2020
Q2 		$792K Sell
64,261
-4,611
-7% -$52.1K ﹤0.01% 1827
2020
Q1 		$618K Sell
68,872
-18,321
-21% -$188K ﹤0.01% 1768
2019
Q4 		$854K Buy
87,193
+6,006
+7% +$53.6K ﹤0.01% 1791
2019
Q3 		$559K Buy
+81,187
New +$622K ﹤0.01% 1848
2016
Q3 		– Sell
-56,971
Closed -$2.86M – 1830
2016
Q2 		$2.86M Buy
56,971
+443
+0.8% +$23.6K 0.01% 646
2016
Q1 		$3.02M Sell
56,528
-53,389
-49% -$3.13M 0.01% 628
2015
Q4 		$7.21M Sell
109,917
-5,798
-5% -$358K 0.03% 514
2015
Q3 		$6.53M Sell
115,715
-1,765
-2% -$114K 0.03% 535
2015
Q2 		$6.94M Buy
117,480
+30,605
+35% +$1.89M 0.03% 538
2015
Q1 		$5.41M Buy
+86,875
New +$5.05M 0.02% 533

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Victory Capital Management's TEVA Position: Q2 2026 in Review

Victory Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 14% in Q2 2026, selling an estimated $8.77M and leaving 1,575,098 shares worth $53.4M. The position accounts for 0.03% of the portfolio, ranked #549.

Victory Capital Management first reported a position in TEVA in Q1 2015 and has held it in 34 quarters since. The position peaked at $66.6M in Q4 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Victory Capital Management held 1,575,098 shares of Teva Pharmaceuticals worth $53.4M as of Q2 2026.
  • Victory Capital Management sold 263,339 Teva Pharmaceuticals shares in Q2 2026, an estimated $8.77M.
  • Teva Pharmaceuticals made up 0.03% of Victory Capital Management's portfolio in Q2 2026, its #549 holding.
  • Victory Capital Management first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 34 quarters since.
  • Victory Capital Management's Teva Pharmaceuticals position peaked at $66.6M in Q4 2024.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.